Abstract
Ovarian cancer, with its asymptomatic early stages, poses a significant challenge for early diagnosis and survival improvement. The utilization of tumor markers, including CA -125 and HE4 has become crucial in detecting these silent killers. Additionally, gene-based markers like BRCA1 and BRCA2 mutations are increasingly acknowledged for indicating ovarian cancer susceptibility. Promising emerging biomarkers, such as microRNAs and circulating tumor cells, offer new research avenues and diagnostic possibilities for the early detection of ovarian cancer. This article provides a comprehensive review of current specific markers, gene-based indicators, emerging markers, and other notable approaches in the early identification of ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
